This second‐generation somatostatin receptor analogue, with its enhanced affinity for somatostatin receptor subtype 5 (SSTR5), effectively inhibits excessive insulin secretion, one of the factors in insulinoma and NICTH.25, 26. Here, SSTR5 is linked to pancreatic insulinoma.